0.094
0.00 (2.07%)
| Previous Close | 0.092 |
| Open | 0.092 |
| Volume | 4,500,385 |
| Avg. Volume (3M) | 15,417,863 |
| Market Cap | 7,023,986 |
| Price / Book | 0.250 |
| 52 Weeks Range | |
| Earnings Date | 31 Mar 2025 - 4 Apr 2025 |
| Diluted EPS (TTM) | -1,943.50 |
| Total Debt/Equity (MRQ) | 5.28% |
| Current Ratio (MRQ) | 3.43 |
| Operating Cash Flow (TTM) | -17.11 M |
| Levered Free Cash Flow (TTM) | -13.27 M |
| Return on Assets (TTM) | -179.08% |
| Return on Equity (TTM) | -1,703.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | CNS Pharmaceuticals, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | -0.38 |
|
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.40% |
| % Held by Institutions | 2.40% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Barrett & Company, Inc. | 31 Mar 2025 | 100 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |